Shares of PTC Therapeutics surged Monday when the pharmaceutical firm announced it struck a nearly $2 billion license and collaboration deal with Novartis.
“If you look at this list of policies and others, all of them have the impact that over time inflation will be higher, growth is going to be lower,” Roubini—a.k.a. Dr. Doom—said this week.